

About Lilly

We're a [medicine company](#) turning science into healing to make life better for people around the world. For nearly 150 years, our research and development (R&D) legacy has resulted in the development of more than [100 medicines](#) across some of the most challenging diseases. Our scientists are harnessing the power of biotechnology to urgently advance new discoveries with the potential to radically transform cardiometabolic health care – and change lives.

Making life better for people with diabetes has been our heartbeat for the [last 100 years](#). Since Lilly launched the world's first commercially available insulin in 1923, we've never stopped pushing the boundaries of research and science to improve diabetes care. Our focus remains on breakthroughs and curative approaches to improve the lives of people with type 1 and type 2 diabetes, such as investigating novel therapeutic approaches that simplify glycemic control.



Lilly's Commitment to Innovation

Pipeline

Learn more about medicines in development at Lilly [here](#).

Clinical Trials

Clinical trials make finding new and improved medicines possible. And we can't conduct trials without help from people like you. Learn more about Lilly clinical trials [here](#).

Recent News Releases

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity. Learn more here: [News Release – Aug. 26, 2025](#)

Lilly reports second-quarter 2025 financial results and raises guidance.

The available earnings presentation contains a wealth of information on the Lilly pipeline, key events and select clinical trials. Of particular note are slides 13-17, 28, 31-33, 36-38, 41-42, and 44-46. Learn more here: [Q2 2025 Earnings Presentation – Aug. 7, 2025](#)

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity.

Learn more here: [News Release - Aug. 7, 2025](#)

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease.

Learn more here: [News Release - Jul. 31, 2025](#)

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials. Learn more here: [News Release - Jun. 22, 2025](#)

Lilly Supports Camps

Lilly understands how important camps are for children with diabetes and that's why we've been supporting camps in the U.S. since 2001. Over the last two decades, Lilly has provided: \$55 million in insulin and other medicines; \$2.5 million in scholarships (that's over 1,800 campers!); dedicated volunteers through the Lilly Gives employee volunteer program; \$1 million commitment with The Leona M. and Harry B. Helmsley Charitable Trust through the Type1 Diabetes Camps Initiative.

Social Impact

We work every day with the goal of growing our business in responsible and sustainable ways that better people's lives and benefit society.

Our impact starts with the purpose of our business: to create medicines that make life better. We're committed to expanding equitable access to medicines for more people around the world, and we are working to improve public health for vulnerable people living in areas with limited resources. We further extend our impact by strengthening communities and addressing social issues – like inequity and education – that matter to our business, employees and society. And when there's a health crisis, like COVID-19, Lilly steps up for the common good. Because it's the right thing to do.

30x30

Globally, we've established a goal – [Lilly 30x30](#) – to provide improved access to quality health care for 30 million people living in resource-limited settings annually by 2030. This is a company-wide effort and includes strategic collaborations with external organizations, such as the Bill & Melinda Gates Foundation, and donations supporting nonprofit organizations, including the Lilly Foundation, the Lilly Cares Foundation and Life for a Child.

30x30
Reach 30 million people in resource-limited settings annually by 2030

We use a mix of philanthropy and shared value-based approaches to improve health systems and concentrate on diseases where we have deep technical expertise, including diabetes, cancer and, COVID-19.

Life for a Child

Lilly is a longstanding supporter of the [Life for a Child](#) (LFAC) program, which provides diabetes education and care for children and young adults with type 1 diabetes (T1D) in low-to middle-income countries. This collaboration aims to improve outcomes by providing insulin, delivery devices, blood glucose monitoring, A1C testing, and diabetes education. By 2030, LFAC, through support from Lilly, aims to expand access to care to approximately 150,000 children and young people across 65 countries.

LIFE FOR A CHILD



Health Above All

Lilly's Approach

Obesity (including Obesity and Moderate-to-Severe OSA)

People with obesity are living with a disease—not a choice—and it comes with physical, mental and emotional hurdles. It's time to address misperceptions, eliminate stigma, and imagine a better future for people around the world navigating this disease. Learn more about [Lilly's Approach to Obesity](#).

Lilly has supported professional organizations, institutions, and patient advocacy organizations in their efforts to provide education and destigmatization. Below are just a few examples:

[AACE Journey for Patients with Obesity](#) provides awareness, education and empowerment for patients.

The [EveryBODY Covered](#) campaign works to ensure that everybody has access to evidence-based obesity care options.

The [Supportive Obesity Care](#) website has a simple goal: to equip healthcare professionals with knowledge and tools to provide more respectful, supportive, and compassionate care to patients of all body sizes.

The [Stop Weight Bias](#) campaign is a national campaign with the commitment to raise awareness, put a stop to weight bias and push equality forward.

The [Sleep Is Good Medicine](#) campaign was developed for consumers and health care professionals to elevate sleep as the third pillar of health, equivalent with nutrition and exercise.

Diabetes

While Lilly history is deeply rooted in T1D, we are also committed to innovating for people with type 2 diabetes (T2D).

People living with diabetes face many challenges. Lilly continues to work with advocates and other partners to provide resources and support programs for those living with diabetes as they navigate their journeys. Below are just a few examples:

[dStigmatize](#) is a diaTribe program focused on addressing stigma impacting diabetes.

Beyond Type 1's [Beyond Barriers](#) program is funding organizations breaking down barriers to high quality diabetes care through Mobile Health Access Solutions in 2025!

The [Beyond Diagnosis](#) program provides the first Beginner's Guides (to Thriving with Diabetes), available for type 1 and type 2 diabetes, in English and Spanish.

The [Breakthrough T1D Bag of Hope™](#) is filled with resources for both children newly diagnosed with T1D and their caregivers.

The [CWD Journey Awards](#) provide recognition of the work required to thrive with T1D. Medals marking 5, 10, 25, 50, and 75 years of daily life with diabetes will serve as an inspiration to everyone in the type 1 community.

Policy & Access

Lilly supports making medicines more accessible and affordable to patients. Lilly advocates for improvements to the U.S. health care system that align to our core principles of:

1. encouraging and protecting innovation;
2. fairness and transparency in the biopharma industry and all of health care; and
3. lowering costs at the pharmacy counter for patients who use our medicine.

Of Interest

[The United States Obesity Response Index](#), supported by Lilly, was developed independently by Economist Impact to assess U.S. state efforts to prevent and manage obesity. It highlights where policy intervention is most needed, and which interventions can be effective.

[THE WILL OF THE PEOPLE: Americans Across the Political Spectrum Support Trump Administration Expanding Coverage of Obesity Medications, New Poll Shows](#) news story from Obesity Care Advocacy Network (OCAN) discusses key findings from a recent OCAN survey.

Insulin Affordability

Lilly is committed to helping people with diabetes access affordable medicines. Through the [Lilly Insulin Value Program](#), all Lilly insulins are available for \$35 a month whether you have commercial insurance or no insurance.* These savings cover all Lilly insulins.

*Terms and conditions apply. At retail pharmacies. Government restrictions exclude people enrolled in federal government insurance programs from Lilly's \$35 solutions. But federal law provides that Medicare Part D beneficiaries also pay no more than \$35 per month for insulin.

Lilly Resources

Lilly Medical

[Lilly Medical](#) is your home for medical information, education materials, publications, congress events and professional resources. Lilly-created [medical education resources](#) are available for a number of therapeutic areas, including:

- Endocrinology and Metabolism: [Diabetes](#) and [Hypoglycemia](#)
- Obesity: [Obesity](#) and [Obstructive Sleep Apnea](#)

Lilly-created [education materials for patients](#) are also available for a number of therapeutic areas, including:

- Endocrinology and Metabolism: [Diabetes](#) and [Hypoglycemia](#)
- Obesity: [Obesity](#) and [Obstructive Sleep Apnea](#)

LillyDirect®

[LillyDirect®](#) features content, tools, and services to assist people in navigating the complex healthcare landscape. It provides options for independent telehealth services, an independent in-person care finder tool, and pharmacy solutions that include delivery of select prescription medicines.

Beyond the Numbers

[Beyond the Numbers](#) is a podcast series for healthcare professionals exploring the sensitive but important topic of weight bias for people with T2D and excess weight.

